All In Biotech

Drug Trial Radar · NCT07054359

"HBV unIversal vs Point-Of-Care-based Antiviral treatMent to Prevent Mother-to-child Transmission"

Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 3,200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

3,200

Planned (sponsor's estimate)

Start

Aug 10, 2026

Primary completion

Nov 10, 2028

Study completion Nov 10, 2029

Sponsor

Lead sponsor
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Institut National de la Santé Et de la Recherche Médicale, France
First posted
Jul 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To achieve global elimination of hepatitis B virus (HBV), it is crucial to eliminate HBV mother-to-child transmission (MTCT) by ensuring high coverage of birth dose vaccine and expanding the adoption of peripartum antiviral prophylaxis (PAP) by tenofovir. Current international guidelines require hepatitis B surface antigen (HBsAg)-positive pregnant women to undergo viral load (VL) quantification to identify those at high risk (VL ≥200,000 IU/mL) who should receive PAP. However, VL testing remains inaccessible in many low- and middle-income countries (LMICs), particularly in rural areas. Consequently, in the forthcoming guidelines, the WHO is going to issue a conditional recommendation for administering PAP to all HBsAg-positive women lacking access to VL testing. Although this universal strategy may appear promising for simplifying the diagnostic process, it may result in overtreating the majority of HBsAg-positive pregnant women, estimated at 85% in Africa and 70% in Asia, for whom birth dose vaccine is likely sufficient. Moreover, the real-world applicability of this strategy in LMICs has never been formally tested. As an innovative alternative, the adoption of a rapid point-of-care test for hepatitis B core-related antigen (HBcrAg-RDT) is proposed to identify women eligible for PAP.This test requires only a drop of capillary blood, eliminating the need for electricity or centrifugation, and can provide a reliable result within 45 minutes. Compared to the universal strategy, HBcrAg-RDT strategy is expected to be less expensive and could prevent unnecessary tenofovir exposure for both women and their fetuses. Our aim is to establish the non-inferiority of the HBcrAg-RDT strategy, in comparison to the universal strategy, in terms of effectiveness, defined as the reduction in maternal VL at the time of childbirth, a main driver of the MTCT risk. This will be approached through a multidisciplinary framework integrating health economics, implementation science, and health policy analysis.

Conditions

  • HBV Infection
  • Pregnancy

Interventions

  • HBsAg RDT WomenDiagnostic test

    HBsAg will be screened using finger-stick capillary blood during the ANC visit, simultaneously with the HIV test

  • Treatment by TDF if HBcrAg RDT positiveDrug

    300mg per day or 300 mg every 2 days (if créatinine clearance is 30-50ml/min)

  • Treatment by TDFDrug

    300mg per day or 300 mg every 2 days (if créatinine clearance is 30-50ml/min)

  • Social sciences componentOther

    The social sciences component only in Cambodia and Ivory Coast. 3 key sub-studies: i) a socio-economic and behavioral study ii) a health economic evaluation study, and iii) a health policy study. A mixed-methods approach will be used, including qualitative interviews and quantitative questionnaires among pregnant women and healthcare workers

  • HBsAg RDT InfantsDiagnostic test

    At 9 months, all infants will be tested for HBsAg; HBsAg-positive infants will undergo HBV DNA testing, and DBS will be collected for biobank storage.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of HBsAg-positive women with HBV DNA <200,000 IU/mL at the time of deliveryTime frame: Delivery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tien lang District Health center

    Haiphong, Vietnam · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.